U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Description

Teriparatide was manufactured under the brand name FORTEO. FORTEO contains recombinant human parathyroid hormone (1-34), [rhPTH(1-34)], which has an identical sequence to the 34 N-terminal amino acids (the biologically active region) of the 84-amino acid human parathyroid hormone, that regulates calcium and phosphate in the body. FORTEO is indicated for the treatment of postmenopausal women with severe osteoporosis who are at high risk of fracture or who have failed or are intolerant to previous osteoporosis therapy. In addition, Forteo is used for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in men and women who are at increased risk for fracture. The biological actions of teriparatide is mediated through binding to specific high-affinity cell-surface receptors. Teriparatide is not expected to accumulate in bone or other tissues.

Approval Year

1987
121
Targets

Targets

Primary TargetPharmacologyConditionPotency
Parathyroid hormone/parathyroid hormone-related peptide receptor
2
Target ID: Q03431
Gene ID: 5745.0
Gene Symbol: PTH1R
Target Organism: Homo sapiens (Human)
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
FORTEO

Approved Use

FORTEO is indicated for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture. These include women with a history of osteoporotic fracture, or who have multiple risk factors for fracture, or who have failed or are intolerant of previous osteoporosis therapy, based upon physician assessment. In postmenopausal women with osteoporosis, FORTEO increases BMD and reduces the risk of vertebral and nonvertebral fractures. FORTEO is indicated to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. These include men with a history of osteoporotic fracture, or who have multiple risk factors for fracture, or who have failed or are intolerant to previous osteoporosis therapy, based upon physician assessment. In men with primary or hypogonadal osteoporosis, FORTEO increases BMD. The effects of FORTEO on risk for fracture in men have not been studied.

Launch Date

2002
PubMed

PubMed

TitleDatePubMed
Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is protein kinase C-dependent and involves beta-arrestin2. Real-time monitoring by fluorescence microscopy.
1999 Oct 15

Sample Use Guides

In Vivo Use Guide
The recommended dosage is 20 mcg once a day.
Route of Administration: Other
Substance Class Protein
Created
by admin
on Mon Mar 31 20:36:00 GMT 2025
Edited
by admin
on Mon Mar 31 20:36:00 GMT 2025
Protein Type HORMONE
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
10T9CSU89I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TERIPARATIDE (GENETICAL RECOMBINATION)
JAN  
Preferred Name English
TERIPARATIDE
EMA EPAR   HSDB   INN   MART.   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
TERIPARATIDE [HSDB]
Common Name English
TERIPARATIDE [VANDF]
Common Name English
TERIPARATIDE [ORANGE BOOK]
Common Name English
Teriparatide [WHO-DD]
Common Name English
ZT-034
Code English
LY 333334
Code English
TERIPARATIDE RECOMBINANT HUMAN
ORANGE BOOK  
Common Name English
TERIPARATIDE [USAN]
Common Name English
TERIPARATIDE RDNA
Common Name English
TERIPARATIDE [USP-RS]
Common Name English
FORSTEO
Brand Name English
TERIPARATIDE [EP MONOGRAPH]
Common Name English
TERIPARATIDE RECOMBINANT HUMAN [ORANGE BOOK]
Common Name English
PARATHYROID HORMONE (1-34)HUMAN SYNTHETIC
Common Name English
(1-34)-HUMAN PARATHYROID HORMONE
Common Name English
PTH (1-34)
Common Name English
1-34-HUMAN PTH
Common Name English
TERIPARATIDE [MART.]
Common Name English
FORTEO
Brand Name English
TERIPARATIDE [USP MONOGRAPH]
Common Name English
LY-333334
Code English
LY333334
Code English
TERIPARATIDE [EMA EPAR]
Common Name English
TERIPARATIDE [JAN]
Common Name English
BONSITY
Brand Name English
SER-VAL-SER-GLU-ILE-GLN-LEU-MET-HIS-ASN-LEU-GLY-LYS-HIS-LEU-ASN-SER-MET-GLU-ARG-VAL-GLU-TRP-LEU-ARG-LYS-LYS-LEU-GLN-ASP-VAL-HIS-ASN-PHE
Common Name English
HUMAN PARATHYROID HORMONE 1-34
Common Name English
teriparatide [INN]
Common Name English
SYNTHETIC HUMAN PARATHYROID HORMONE 1-34
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS FORSTEO (AUTHORIZED: OSTEOPOROSIS)
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
EMA ASSESSMENT REPORTS FORSTEO (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
WHO-VATC QH05AA02
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
EU-Orphan Drug EU/3/16/1689
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
NCI_THESAURUS C62555
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
FDA ORPHAN DRUG 14486
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
FDA ORPHAN DRUG 138100
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
LIVERTOX NBK548722
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
WHO-ATC H05AA02
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
FDA ORPHAN DRUG 425814
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
FDA ORPHAN DRUG 127099
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
NDF-RT N0000180852
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
NDF-RT N0000011221
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
Code System Code Type Description
JAPANESE REVIEW
FORTEO
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY APPROVED JULY 2010
SMS_ID
100000089193
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
EVMPD
SUB10925MIG
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
WIKIPEDIA
TERIPARATIDE
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
EPA CompTox
DTXSID001027900
Created by admin on Mon Mar 31 20:36:01 GMT 2025 , Edited by admin on Mon Mar 31 20:36:01 GMT 2025
PRIMARY
DRUG BANK
DB06285
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
RS_ITEM_NUM
1643962
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
RXCUI
32915
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY RxNorm
IUPHAR
4448
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
DAILYMED
10T9CSU89I
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
FDA UNII
10T9CSU89I
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
INN
5411
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
NCI_THESAURUS
C61966
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
ChEMBL
CHEMBL525610
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
CAS
52232-67-4
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
HSDB
7367
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
DRUG CENTRAL
4514
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
USAN
II-54
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
MESH
D019379
Created by admin on Mon Mar 31 20:36:00 GMT 2025 , Edited by admin on Mon Mar 31 20:36:00 GMT 2025
PRIMARY
Related Record Type Details
TERIPARATIDE ACETATE
INGREDIENT -> STARTING MATERIAL
TERIPARATIDE ACETATE
SALT/SOLVATE -> PARENT
Related Record Type Details
PALOPEGTERIPARATIDE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
TERIPARATIDE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966